Elicera Therapeutics AB (FRA:8E8) Inventories, Raw Materials & Components: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8E8 Elicera Therapeutics AB FRA:8E8
40 GF Score
Price €0.21
! 1 Warning Sign
View Full Analysis

What is Elicera Therapeutics AB Inventories, Raw Materials & Components?

Elicera Therapeutics AB FRA:8E8 -3.87% 40 Inventories, Raw Materials & Components is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:8E8 with a GF Score™ of 40/100. The stock has 1 warning sign investors should review.

Elicera Therapeutics AB's inventories, raw materials & components for the quarter that ended in Mar. 2026 was €0.00 Mil.

Elicera Therapeutics AB Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for Elicera Therapeutics AB's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elicera Therapeutics AB Inventories, Raw Materials & Components Chart

Elicera Therapeutics AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Elicera Therapeutics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:8E8
40GF Score
Elicera Therapeutics AB FRA:8E8
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elicera Therapeutics AB Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of €0.00 Mil mean?
Elicera Therapeutics AB (FRA:8E8) has a Inventories, Raw Materials & Components of €0.00 Mil as of Mar. 2026. Raw materials are the components a company uses for its main products. View historical data on Elicera Therapeutics AB and its competitors.
Is Elicera Therapeutics AB's Inventories, Raw Materials & Components too high?
Elicera Therapeutics AB's current Inventories, Raw Materials & Components is €0.00 Mil. Overall, Elicera Therapeutics AB has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Elicera Therapeutics AB's Inventories, Raw Materials & Components compare to VRTX and REGN?
Elicera Therapeutics AB's Inventories, Raw Materials & Components of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Biotechnology company?
A good Inventories, Raw Materials & Components depends on the Biotechnology industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Elicera Therapeutics AB and its competitors. Elicera Therapeutics AB's current Inventories, Raw Materials & Components is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elicera Therapeutics AB stock overvalued right now?
Elicera Therapeutics AB (FRA:8E8) has a current Inventories, Raw Materials & Components of €0.00 Mil. The current Inventories, Raw Materials & Components is €0.00 Mil. Elicera Therapeutics AB's overall GF Score™ is 40/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Elicera Therapeutics AB (FRA:8E8), the current Inventories, Raw Materials & Components is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Elicera Therapeutics AB Business Description

Other Exchanges ELIC:Sweden
Address Massans gata 10, World Trade Center Goteborg, 7th Floor, Goteborg, SWE, 412 51
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. Its product portfolio consists of four drug candidates, including two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to the universal CAR T-cell technology platform, iTANK (ELC-001). The Company is running four internal immunotherapy development projects, comprising two CAR T-cell programs and two oncolytic virus programs.
40GF Score

Get the complete analysis for FRA:8E8

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.21
Price